Pfizer Inc. Share Price Target ‘$32.38’, now 8.9% Upside Potential

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

Pfizer Inc. which can be found using ticker (PFE) now have 21 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between $50.00 and $23.00 with the average share target price sitting at $32.38. (at the time of writing). Now with the previous closing price of $29.73 this now indicates there is a potential upside of 8.9%. The 50 day moving average now sits at $29.41 while the 200 day moving average is $34.98. The company has a market capitalization of 167.87B. The stock price for the company is currently $29.09 USD

The potential market cap would be $182,830,906,968 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 16.25, revenue per share of $12.16 and a 2.39% return on assets.

Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operates through two segments: Biopharma and PC1. Biopharma is engaged in the science-based biopharmaceutical business. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. The Company’s primary care products include Eliquis, Nurtec ODT/Vydura and the Premarin family; the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac and Trumenba; Comirnaty, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Eucrisa/Staquis and Cibinqo; the Vyndaqel family, Oxbryta, BeneFIX and Genotropin, and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend and Panzyga. Its oncology products include Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena and Braftovi.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

      Search

      Search